Moran Wealth Management LLC Has $4.97 Million Holdings in Fresenius Medical Care AG (NYSE:FMS)

Moran Wealth Management LLC raised its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 47.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 233,376 shares of the company's stock after purchasing an additional 74,621 shares during the quarter. Moran Wealth Management LLC's holdings in Fresenius Medical Care were worth $4,971,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wulff Hansen & CO. raised its holdings in shares of Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock worth $6,556,000 after buying an additional 325,439 shares in the last quarter. Triasima Portfolio Management inc. boosted its stake in shares of Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company's stock valued at $1,631,000 after purchasing an additional 18,360 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock worth $1,340,000 after purchasing an additional 23,692 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Fresenius Medical Care by 10.9% during the 2nd quarter. QRG Capital Management Inc. now owns 60,309 shares of the company's stock worth $1,151,000 after purchasing an additional 5,946 shares in the last quarter. Finally, Creative Planning lifted its holdings in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company's stock valued at $766,000 after purchasing an additional 6,373 shares during the last quarter. Institutional investors own 8.25% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on FMS shares. Truist Financial increased their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Saturday, November 9th. They issued a "strong-buy" rating for the company. Finally, Berenberg Bank started coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a "buy" rating and a $25.60 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $24.30.

Fresenius Medical Care Stock Up 0.9 %

Shares of FMS stock traded up $0.19 on Thursday, hitting $21.98. 196,198 shares of the stock were exchanged, compared to its average volume of 364,587. The business has a 50-day moving average of $20.78 and a 200 day moving average of $20.27. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $22.76. The firm has a market capitalization of $12.90 billion, a P/E ratio of 18.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.91. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.